MASSDEVICE ON CALL — The medical device world will be watching intently this weekend as Medtronic (NYSE:MDT) releases data for the 1st time from a failed clinical trial of its Symplicity renal denervation device.
Medtronic is slated to present its initial findings from the Symplicity HTN-3 study tomorrow at the American College of Cardiology’s annual meeting in Washington.
News that the trial, widely expected to lead to a nod from the FDA for treating hypertension, failed to meet its primary efficacy endpoint shocked medtech late last year – especially the other major players in the RDN game.
St. Jude Medical (NYSE:STJ) sought a cautious tone in reaction to the bombshell, but Boston Scientific (NYSE:BSX) suspended its Vessix RDN program and Covidien (NYSE:COV) abandoned the field altogether.
Stay tuned to MassDevice.com tomorrow for the news on the Symplicity HTN-3 data from Washington.
House votes to delay Medicare rate cut – again
The U.S. Congress moved yesterday to prevent a 24% Medicare reimbursement rate cut, despite a last-minute protest from the American Medical Assn., which wants to repeal the formula used to calculate how the government health insurer pays physicians. If the bill makes it into law it will be the 17th time in 10 years Congress has moved to dodge the sustainable growth rate.
GAO: VA’s IT security needs improvement
The U.S. Government Accountability Office said this week that the U.S. Veterans Affairs Dept. still faces "long-standing"information security problems that leave veterans’ confidential personal information vulnerable. The House Committee on Veterans’ Affairs subcommittee is mulling draft legislation to bolster IT security at the VA.
Study: The rise & fall of nuclear myocardial perfusion imaging
The number of nuclear MPI tests rose by 41% from 2000 to 2006 among members of the Kaiser Permanente healthcare plan in Northern California, but plunged 51% from 2006 to 2011, according to a study in the Journal of the American Medical Assn.